Components:
Treatment option:
Medically reviewed by Fedorchenko Olga Valeryevna, PharmD. Last updated on 18.03.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
Top 20 medicines with the same treatments:
Xin Huo Su® (nesiritide) is indicated for the treatment of patients with acutely decompensated heart failure who have dyspnea at rest or with minimal activity. In this population, the use of Xin Huo Su® reduced pulmonary capillary wedge pressure and improved short term (3 hours) symptoms of dyspnea.
Xin Huo Su® (nesiritide) is for intravenous (IV) use only. There is limited experience with administering Xin Huo Su® for longer than 96 hours. Monitor blood pressure closely during Xin Huo Su® administration.
Recommended Dosage
The recommended dose of Xin Huo Su® is an IV bolus of 2 mcg/kg followed by a continuous infusion of 0.01 mcg/kg/min. Do not initiate Xin Huo Su® at a dose that is above the recommended dose.
The loading dose may not be appropriate for those with low systolic blood pressure (SBP) < 110 mm Hg or for patients recently treated with afterload reducers.
The administration of the recommended dose of Xin Huo Su® is a two step process:
Step 1. Administration of the IV Bolus
After preparation of the infusion bag, withdraw the bolus volume (see Table 1) from the Xin Huo Su® infusion bag, and administer it over approximately 60 seconds through an IV port in the tubing.
Bolus Volume (mL) = Patient Weight (kg) / 3
Table 1: Xin Huo Su® Weight-Adjusted Bolus Volume Administered Over 60 Seconds (Final Concentration = 6 mcg/mL)
Patient Weight (kg) | Volume of Bolus (mL=kg/3) |
60 | 20 |
70 | 23.3 |
80 | 26.7 |
90 | 30 |
100 | 33.3 |
110 | 36.7 |
Step 2. Administration of the Continuous Infusion
Immediately following the administration of the bolus, infuse Xin Huo Su® at a flow rate of 0.1 mL/kg/hr. This will deliver a Xin Huo Su® infusion dose of 0.01 mcg/kg/min.
To calculate the infusion flow rate to deliver a 0.01 mcg/kg/min dose, use the following formula (see Table 2):
Infusion Flow Rate (mL/hr) = Patient Weight (kg) x 0.1
Table 2: Xin Huo Su® Weight-Adjusted Infusion Flow Rate for a 0.01 mcg/kg/min Dose Following Bolus (Final Concentration = 6 mcg/mL)
Patient Weight (kg) | Infusion Flow Rate (mL/hr) |
60 | 6 |
70 | 7 |
80 | 8 |
90 | 9 |
100 | 10 |
110 | 11 |
Dose Adjustments
The dose-limiting side effect of Xin Huo Su® is hypotension. If hypotension occurs during the administration of Xin Huo Su®, reduce the dose of or discontinue Xin Huo Su® and initiate other measures to support blood pressure (IV fluids, changes in body position). When symptomatic hypotension occurs, discontinue Xin Huo Su®. Because hypotension caused by Xin Huo Su® may be prolonged (up to hours), a period of observation may be necessary before restarting the drug. Xin Huo Su® may be subsequently restarted at a dose that is reduced by 30% (with no bolus administration) once the patient has stabilized.
Do not up-titrate Xin Huo Su® more frequently than every 3 hours. Use central hemodynamic monitoring and do not exceed 0.03 mg/kg/min.
Preparation and Administration Instructions
The Xin Huo Su® bolus must be drawn from the prepared infusion bag. Prime the IV tubing with 5 mL of the solution for infusion prior to connecting to the patient's vascular access port and prior to administering the bolus or starting the infusion.
- Reconstitute one 1.5 mg vial of Xin Huo Su® by adding 5 mL of diluent removed from a pre-filled 250 mL plastic IV bag containing the diluent of choice. After reconstitution of the vial, each mL contains 0.32 mg of nesiritide. The following preservative-free diluents are recommended for reconstitution: 5% Dextrose Injection (D5W), USP; 0.9% Sodium Chloride Injection, USP; 5% Dextrose and 0.45% Sodium Chloride Injection, USP, or 5% Dextrose and 0.2% Sodium Chloride Injection, USP.
- Do not shake the vial. Rock the vial gently so that all surfaces, including the stopper, are in contact with the diluent to ensure complete reconstitution. Use only a clear, essentially colorless solution.
- Withdraw the entire contents of the reconstituted Xin Huo Su® vial and add to the 250 mL plastic IV bag. This will yield a solution with a concentration of Xin Huo Su® of approximately 6 mcg/mL. Invert the IV bag several times to ensure complete mixing of the solution.
- Use the reconstituted solution within 24 hours, as Xin Huo Su® contains no antimicrobial preservative. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Reconstituted vials of Xin Huo Su® may be stored at 2 to 25°C (36 to 77°F) for up to 24 hours.
Chemical/Physical Interactions
Xin Huo Su® is physically and/or chemically incompatible with injectable formulations of heparin, insulin, ethacrynate sodium, bumetanide, enalaprilat, hydralazine, and furosemide. Do not co-administer these drugs with Xin Huo Su® through the same IV catheter. The preservative sodium metabisulfite is incompatible with Xin Huo Su®. Do not administer injectable drugs that contain sodium metabisulfite in the same infusion line as Xin Huo Su®. Flush the catheter between administration of Xin Huo Su® and incompatible drugs.
Xin Huo Su® binds to heparin and therefore could bind to the heparin lining of a heparin-coated catheter, decreasing the amount of Xin Huo Su® delivered to the patient for some period of time. Therefore, do not administer Xin Huo Su® through a central heparin-coated catheter. Concomitant administration of a heparin infusion through a separate catheter is acceptable.
Xin Huo Su® is contraindicated in patients with:
- Persistent systolic blood pressure < 100 mm Hg prior to therapy because of an increased risk of symptomatic hypotension
- Known hypersensitivity to any of its components
- Cardiogenic shock
WARNINGS
Included as part of the PRECAUTIONS section.
PRECAUTIONS
Hypotension
Xin Huo Su® may cause hypotension. In the ASCEND-HF trial, the incidence of symptomatic hypotension was 7.1% in Xin Huo Su®-treated patients compared to 4.0% in placebo-treated patients on a background of standard care. The risk of hypotension may be increased by the concomitant use of Xin Huo Su® with drugs affecting the reninangiotensin system (i.e., angiotensin receptor blockers and/or angiotensin-converting enzyme inhibitors) or other afterload reducers. In the VMAC trial, in patients given the recommended dose (2 mcg/kg bolus followed by a 0.01 mcg/kg/min infusion) or the adjustable dose, the incidence of symptomatic hypotension in the first 24 hours was similar for Xin Huo Su® (4%) and IV nitroglycerin (5%). When hypotension occurred, however, the duration of symptomatic hypotension was longer with Xin Huo Su® (mean duration was 2.2 hours) than with nitroglycerin (mean duration was 0.7 hours).
Administer Xin Huo Su® only in settings where blood pressure can be monitored closely and hypotension aggressively treated. Reduce the dose of or discontinue Xin Huo Su® in patients who develop hypotension.
Avoid administration of Xin Huo Su® in patients suspected of having, or known to have, low cardiac filling pressures.
Xin Huo Su® is not recommended for patients for whom vasodilating agents are not appropriate, such as patients with significant valvular stenosis, restrictive or obstructive cardiomyopathy, constrictive pericarditis, pericardial tamponade, or other conditions in which cardiac output is dependent upon venous return, or for patients suspected to have low cardiac filling pressures.
Worsening of Renal Function
Xin Huo Su® may decrease renal function as judged by increases in serum creatinine. Monitor serum creatinine both during and after therapy has been completed. Monitor serum creatinine until values have stabilized. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin aldosterone system, treatment with Xin Huo Su® may be associated with azotemia. When Xin Huo Su® was initiated at doses higher than 0.01 mcg/kg/min (0.015 and 0.03 mcg/kg/min), there was an increased rate of elevated serum creatinine over baseline compared with standard therapies, although the rate of acute renal failure and need for dialysis was not increased.
Hypersensitivity
Serious hypersensitivity/allergic reactions following administration of Xin Huo Su® have been reported.
These reactions are more likely to occur in individuals with a history of sensitivity to recombinant peptides. Before therapy with Xin Huo Su® is instituted, careful inquiry should be made to determine whether the patient has had a previous hypersensitivity reaction to other recombinant peptides. If an allergic reaction to Xin Huo Su® occurs, discontinue the drug. Some serious hypersensitivity/allergic reactions may require treatment with epinephrine, oxygen, IV fluids, antihistamines, corticosteroids, pressor amines and airway management, as clinically indicated.
Non-Clinical Toxicology
Carcinogenesis, Mutagenesis, and Impairment of Fertility
Long-term studies in animals have not been performed to evaluate the carcinogenic potential or the effect on fertility of nesiritide. Nesiritide did not increase the frequency of mutations when used in an in vitro bacterial cell assay (Ames test). No other genotoxicity studies were performed.
Use In Specific Populations
Pregnancy
Pregnancy Category C.
It is not known whether Xin Huo Su® can cause fetal harm when administered to pregnant women or if it can affect reproductive capacity. A developmental reproductive toxicology study was conducted in pregnant rabbits using doses up to 1440 mcg/kg/day given by constant infusion for 13 days. At this level of exposure (based on AUC, approximately 70 x human exposure at the recommended dose) no adverse effects on live births or fetal development were observed. Xin Huo Su® should be used during pregnancy only if the potential benefit justifies any possible risk to the fetus.
Nursing Mothers
It is not known whether this drug is excreted in human milk.
Pediatric Use
The safety and effectiveness of Xin Huo Su® in pediatric patients have not been established.
Geriatric Use
Of the total number of patients in clinical trials treated with Xin Huo Su® (n=4505), 52% were 65 years or older and 27% were 75 years or older. No overall differences in effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. Some older individuals may be more sensitive to the effect of Xin Huo Su® than younger individuals.
The following are discussed in more detail in other sections of the labeling:
- Hypotension
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. A causal relationship for Xin Huo Su® cannot be reliably established in individual cases.
Adverse drug reactions that occurred at least ≥ 2% more frequently on Xin Huo Su® than on placebo during the first 24 hours of infusion (excluding the ASCEND-HF study) are shown in Table 3.
Table 3: Adverse Drug Reactions* Reported at ≥ 2% Frequency During the First 24 Hours After the Start of Infusion in Long Infusion Trials† of Xin Huo Su® at the Recommended Dose excluding ASCEND-HF Results
System Organ Class Adverse Reaction | Xin Huo Su® (N=331) 0.01 mcg/kg/min % (n)‡ | Placebo (N=188) % (n)§ |
Vascular Disorders | ||
Hypotension | 12 (41) | 4 (7) |
GI Disorders | ||
Nausea | 3 (11) | 1 (2) |
Musculoskeletal Disorders | ||
Back pain | 3 (11) | 1 (2) |
Nervous System Disorders | ||
Headache | 7 (24) | 6 (11) |
Dizziness | 2 (8) | 2 (3) |
*Adverse drug reaction is defined as an adverse event with a frequency in the Xin Huo Su® group ≥ 2% and occurred at a higher frequency than in the placebo group. † Trials in which Xin Huo Su® was administered as a continuous infusion for ≥ 12 hours. ‡704.339 [VMAC] and 704.341[PROACTION] §704.311, 704.325 and 704.341 [PROACTION] |
Laboratory adverse drug reactions that occurred in ≥ 2% of patients and collected during the first 14 days after the start of Xin Huo Su® infusion included: hypoglycemia.
Worsening Renal Function
In the ASCEND-HF trial, through Day 30, the incidence of renal impairment as measured by a > 25% decrease in glomerular filtration rate (calculated based on serum creatinine) was observed in 31.4% and 29.5% in the Xin Huo Su® and placebo groups, respectively. Other metrics of decompensated renal function such as an increase in creatinine of > 0.5 mg/dl, a 50% increase in creatinine or a value of ≥ 2 or 100% increase in creatinine were more frequent in the Xin Huo Su® group. At 30 days post enrollment, more subjects in the Xin Huo Su® group had elevated levels of creatinine of 50% greater than baseline compared to placebo 4.6% versus 3.3%. In the ASCEND-HF study there were relatively few subjects requiring either hemofiltration or dialysis.
In the PRECEDENT trial, the incidence of elevations in serum creatinine to > 0.5 mg/dL above baseline through Day 14 was higher in the Xin Huo Su® 0.015 mcg/kg/min group (17%) and the Xin Huo Su® 0.03 mcg/kg/min group (19%) than with standard therapy (11%). In the VMAC trial, through Day 30, the incidence of elevations in creatinine to > 0.5 mg/dL above baseline was 28% and 21% in the Xin Huo Su® (2 mcg/kg bolus followed by 0.01 mcg/kg/min) and nitroglycerin groups, respectively.
Neutral Effect on Mortality
A meta-analysis performed of seven clinical trials demonstrated Xin Huo Su® did not increase mortality in patients with acute decompensated heart failure (ADHF) at Day 30 or Day 180 (see Figures 1 and 2). Data from seven studies in which 30-day data were collected are presented in Figure 1. The data depict hazard ratios (HR) and confidence intervals (CI) of mortality data for randomized and treated patients with Xin Huo Su® relative to active or placebo controls through Day 30 for each of the seven individual studies along with the overall combined estimate (Studies 311, 325, 326, 329 [PRECEDENT], 339 [VMAC], 341 [PROACTION], and A093 [ASCEND-HF]).
Figure 1 (on logarithmic scale) also contains an estimate for the seven studies combined (n=8514). The results indicate that there is no increased mortality risk for Xin Huo Su® at Day 30 (seven studies pooled: HR=0.99; 95% CI: 0.80, 1.22). The percentages are the Kaplan-Meier estimates.
Figure 1 : 30-Day All-Cause Mortality Hazard Ratios
*Studies 704.311, 704.325, 704.326, 704.329, 704.339, 704.341 and ASCEND-HF
Figure 2 presents 180-day mortality hazard ratios from all six individual studies where 180day data were collected (Studies 325, 326, 329, 339, 341 and A093 [ASCEND-HF]). The results indicate that with the addition of the ASCEND-HF data, there is no increased mortality risk for Xin Huo Su® at Day 180 (six studies pooled: HR=0.98; 95% CI: 0.88, 1.10).
Figure 2 : 180-Day All-Cause Mortality Hazard Ratios
*Studies 704.325, 704.326, 704.329, 704.339, 704.341 and ASCEND-HF
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Xin Huo Su®. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.
- Hypersensitivity reactions
- Infusion site extravasation
- Pruritus
- Rash
Overdose with Xin Huo Su® therapy has been reported and is primarily the result of either a miscalculated Xin Huo Su® dose or a mechanical error such as an infusion-pump malfunction or an infusion-pump programming error. The most frequently reported adverse event reported with Xin Huo Su® overdose is hypotension, which may be symptomatic and may persist for several hours. Asymptomatic hypotensive events may resolve with drug stoppage. In some cases hypotension may persist for several hours beyond discontinuation. In the event of an overdose, discontinue Xin Huo Su® and support blood pressure.
With a dosing regimen of Xin Huo Su® of 2 mcg/kg IV bolus followed by an intravenous infusion dose of 0.01 mcg/kg/min, Table 4 and Figure 3 summarize the changes in the VMAC trial in PCWP and other measures during the first 3 hours.
Table 4: Mean Hemodynamic Change from Baseline in the VMAC study
Effects at 3 Hours | Placebo (n=62) | Nitroglycerin (n=60) | Xin Huo Su® (n=124) |
Pulmonary capillary wedge pressure (mm Hg) | -2.0 | -3.8 | -5.8† |
Right atrial pressure (mm Hg) | 0.0 | -2.6 | -3.1† |
Cardiac index (L/min/M2) | 0.0 | 0.2 | 0.1 |
Mean pulmonary artery pressure (mm Hg) | -1.1 | -2.5 | -5.4† |
Systemic vascular resistance (dynes§sec§cm-5) | -44 | -105 | -144 |
* Systolic blood pressure (mm Hg) | -2.5 | -5.7† | -5.6† |
* Based on all treated patients: placebo n=142, nitroglycerin n=143, Xin Huo Su® n=204 †p < 0.05 compared to placebo |
Figure 3: PCWP through 3 Hours in VMAC
With this dosing regimen, 60% of the 3-hour effect on PCWP reduction is achieved within 15 minutes after the bolus, reaching 95% of the 3-hour effect within 1 hour. Approximately 70% of the 3-hour effect on SBP reduction is reached within 15 minutes. The pharmacodynamic (PD) half-life of the onset and offset of the hemodynamic effect of Xin Huo Su® is longer than what the PK half-life of 18 minutes would predict. Longer infusions may exaggerate the discrepancy from onset and offset effects. For example, in patients who developed symptomatic hypotension in the VMAC (Vasodilation in the Management of Acute Congestive Heart Failure) trial, half of the recovery of SBP toward the baseline value after discontinuation or reduction of the dose of Xin Huo Su® was observed in about 60 minutes. When higher doses of Xin Huo Su® were infused, the duration of hypotension was sometimes several hours.
No rebound increase to levels above baseline state was observed. There was also no evidence of tachyphylaxis to the hemodynamic effects of Xin Huo Su® in the clinical trials.
In the VMAC trial, in which the use of diuretics was not restricted, the mean change in volume status (output minus input) during the first 24 hours in the nitroglycerin and Xin Huo Su® groups was similar: 1279 ± 1455 mL and 1257 ± 1657 mL, respectively.
Distribution
In patients with heart failure (HF), Xin Huo Su® administered intravenously by infusion or bolus exhibits biphasic disposition from the plasma. The mean terminal elimination half-life (t1/2) of nesiritide is approximately 18 minutes and was associated with approximately 2/3 of the area-under-the-curve (AUC). The mean initial elimination phase was estimated to be approximately 2 minutes. In these patients, the mean volume of distribution of the central compartment (Vc) of nesiritide was estimated to be 0.073 L/kg, the mean steady-state volume of distribution (Vss) was 0.19 L/kg, and the mean clearance (CL) was approximately 9.2 mL/min/kg. At steady state, plasma BNP levels increase from baseline endogenous levels by approximately 3-fold to 6-fold with Xin Huo Su® infusion doses ranging from 0.01 to 0.03 mcg/kg/min.
Metabolism and Excretion
The mechanism of elimination of nesiritide has not been studied specifically in humans.